clinical trial bpc-157 humans If worked as well as the internet says it does… …we'd probably have high quality human trials by now. Instead we have... Lots of rat studies. Lots of podcasts. Lots of Regeneration or Risk? A Narrative

AOD-9604 produces fat loss without any IGF-1 elevation, preserves normal glucose metabolism and insulin sensitivity, does not promote muscle growth or tissue proliferation, shows minimal fluid retention or edema, and requires less intensive monitoring due to absence of systemic effects

See what our customers are saying about their appointments with The Center

Consequently, Enclomiphene remains a recognized research material for controlled laboratory evaluation and comparative investigation

2 : , , In September 2023, the FDA updated the list of bulk drug substances nominated for use under Section 503A a move that has since been followed by additional FDA updates and policy signals, including the September 2024 interim bulks list update